At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 261 enrolled
Drug / intervention
Erenumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Japanese Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention
In Brief
A Phase 3 clinical trial evaluating Erenumab and Placebo for Migraine. Completed, enrolled 261 participants across 41 sites.
Detailed Summary
The purpose of this study was to assess the efficacy and safety of erenumab for prevention of migraine in Japanese adults with episodic migraine (EM) and chronic migraine (CM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartApr 2019
Primary CompletionMar 2020
Study CompletionNov 2020
TodayJul 2026
First PostedJan 23, 2019
Enrollment StartApr 12, 2019
Primary CompletionMar 16, 2020
Study CompletionNov 25, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.4 years ago
Interventions
Erenumabdrug
Administered by subcutaneous injection once a month
Placebodrug
Administered by subcutaneous injection once a month